23255-32-5

Basic information

• Product Name: glycerylcysteine
• Synonyms: glycerylcysteine
• CAS NO: 23255-32-5
• Molecular Formula: C₆H₁₃NO₄S
• Molecular Weight: 195.24
• Mol File: 23255-32-5.mol

Chemical Properties

• Boiling Point: 472.1°Cat760mmHg
• Flash Point: 239.3°C
• Appearance: /
• Density: 1.386g/cm³
• Vapor Pressure: 6.74E-11mmHg at 25°C
• Refractive Index: 1.565
• CAS DataBase Reference: glycerylcysteine(CAS DataBase Reference)
• NIST Chemistry Reference: glycerylcysteine(23255-32-5)
• EPA Substance Registry System: glycerylcysteine(23255-32-5)

Safety Data

• Hazardous Substances Data: 23255-32-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C6H13NO4S/c8-2-4(9)1-7-5(3-12)6(10)11/h4-5,7-9,12H,1-3H2,(H,10,11)/t4?,5-/m0/s1

Upstream product

• 134982-22-2 (R)-2-tert-Butoxycarbonylamino-3-((R)-2,3-dihydroxy-propylsulfanyl)-propionic acid tert-butyl ester 
• 2731-73-9 2-amino-3-chloropropanoic acid 
• 96-27-5 rac-3-sulfanylpropane-1,2-diol 
• 134982-22-2 S-<(2RS)-2,3-Dihydroxypropyl>-N^α-Boc-Cys-OBu^t 
• 4704-77-2 1-bromo-2,3-propanediol 
• 52-89-1 l-cysteine hydrochloride 

Relevant articles and documents

ADMINISTRATION OF A TLR2 AGONIST FOR THE TREATMENT OR PREVENTION OF A RESPIRATORY CONDITION ASSOCIATED WITH AN INFECTIOUS AGENT

The present invention relates to methods of treating or preventing respiratory conditions. In particular, the methods relate to treatment of respiratory conditions associated with a virus, such as influenza. In particular, the present invention provides a method of treating or preventing a respiratory condition associated with an infectious agent in an individual, the method comprising administering a compound comprising a TLR2 agonist to the upper respiratory tract of the individual, thereby treating or preventing a respiratory condition associated with an infectious agent in the individual. The compound is not administered to the lower respiratory tract or to both the upper and lower respiratory tract (i.e. administered to the total respiratory tract).

Double conjugation strategy to incorporate lipid adjuvants into multiantigenic vaccines

Conjugation of multiple peptides by their N-termini is a promising technique to produce branched multiantigenic vaccines. We established a double conjugation strategy that combines a mercapto-acryloyl Michael addition and a copper-catalysed alkyne-azide 1,3-dipolar cycloaddition (CuAAC) reaction to synthesise self-adjuvanting branched multiantigenic vaccine candidates. These vaccine candidates aim to treat cervical cancer and include two HPV-16 derived epitopes and a novel self-adjuvanting moiety. This is the first report of mercapto-acryloyl conjugation applied to the hetero conjugation of two unprotected peptides by their N-termini followed by a CuAAC reaction to conjugate a novel synthetic lipoalkyne self-adjuvanting moiety. In vivo experiments showed that the most promising vaccine candidate completely eradicated tumours in 46% of the mice (6 out of 13 mice).